Results 111 to 120 of about 195,821 (248)

Neuroprotective effects of quercetin in animal models of neurodegenerative diseases: A systematic review and meta‐analysis

Journal of the Science of Food and Agriculture, EarlyView.
Abstract Neurodegenerative conditions such as Alzheimer's disease and Parkinson's disease are characterized by progressive neuronal loss driven by oxidative stress and inflammation. Quercetin, a dietary flavonoid with established antioxidant and anti‐inflammatory properties, has emerged as a potential neuroprotective agent.
In Ho Cho, Hendra Mahakam Putra, Cheol Woon Jung, Gyu Hwan Hyun, Hwan‐Hee Jang, In Guk Hwang, Sung Won Kwon   +6 more
wiley   +1 more source

Impact of Chronic Urticaria on Major Life‐Changing Decisions: Greater Burden in Social, Physical, and Job/Career Domains

JEADV Clinical Practice, EarlyView.
The 32‐item Major Life‐Changing Decision Profile was validated and applied to 111 Turkish‐speaking chronic urticaria patients. Overall, 79.3% reported at least one affected major life‐changing decision, most commonly in social (69.4%), physical (56.8%) and job/career (36.9%) domains. Higher impact was observed in patients with disease onset ≤ 45 years (
Sinem Ornek Ozdemir, Kubra Cure, Defne Baskurt, Rabia Oztas Kara, Muhammed Burak Yucel, Esra Sarac, Pelin Kuteyla Can, Bahar Sevimli Dikicier, Ragip Ertas, Andac Salman, Murat Türk, Utkan Kızıltac, Faraz Mahmood Ali, Sam Salek, Andrew Y. Finlay, Emek Kocaturk   +15 more
wiley   +1 more source

Metabolic Syndrome and Dementia Risk in Older Adults: A Narrative Review

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Dementia is a major global health issue in aging societies. Metabolic syndrome (MetS), a cluster of metabolic abnormalities, has been proposed as a modifiable risk factor for dementia, although existing evidence remains inconsistent. This review examined recent studies on the association between MetS and dementia risk in older adults.
Hyojin Park, Mallika Chuansangeam, Yuan‐Han Yang   +2 more
wiley   +1 more source

Evidence that cholinergic mechanisms contribute to hyperexcitability at early stages in Alzheimer’s disease

Frontiers in Dementia
A long-standing theory for Alzheimer’s disease (AD) has been that deterioration of synapses and depressed neuronal activity is a major contributing factor.
Helen E. Scharfman, Helen E. Scharfman, Helen E. Scharfman, Helen E. Scharfman, Helen E. Scharfman, Korey Kam, Áine M. Duffy, John J. LaFrancois, Paige Leary, Elissavet Chartampila, Stephen D. Ginsberg, Stephen D. Ginsberg, Stephen D. Ginsberg, Stephen D. Ginsberg, Christos Panagiotis Lisgaras, Christos Panagiotis Lisgaras   +15 more
doaj   +1 more source

A Reversible Clearing Strategy Enables Robust Label‐Free Phase Imaging of Thick Tissues

Laser &Photonics Reviews, EarlyView.
The principle of a reversible clearing strategy via glycerol and tartrazine solution (GTS) for robust whole‐slide label‐free phase imaging of thick tissue slices via high‐throughput Fourier ptychographic microscopy (FPM) and lensless digital holographic microscopy (LDHM). ABSTRACT Thick biological specimens impose strong scattering and attenuation that
Mikołaj Krysa, Anna Chwastowicz, Małgorzata Lenarcik, Paweł Matryba, Piotr Zdańkowski, Maciej Trusiak   +5 more
wiley   +1 more source

The Role of microRNA in Overactive Bladder: Relationship and Clinical Correlation

Medicina
Background and Objectives: This study aimed to determine the relationship between miRNAs and overactive bladder (OAB). We also aimed to reveal the diagnostic properties of miRNAs and their potential to predict responses to therapy. Materials and Methods:
Kürşat Küçüker, Hülya Aybek, Hakan Akça, Ege Rıza Karagür, Elif Fırat, Yusuf Özlülerden, Sinan Çelen, Zafer Aybek   +7 more
doaj   +1 more source

Real‐World Patterns of Botulinum Toxin Treatment in Hyperkinetic Movement Disorders: A 9‐Year Nationwide Analysis in France

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Hyperkinetic movement disorders, including dystonia, tremor, and myoclonus, are disabling conditions often managed with botulinum toxin type A (BoNT‐A). Real‐world evidence on treatment patterns remains limited. Objective This nationwide, population‐based study aimed to evaluate trends in BoNT‐A use in France between 2015 and 2023 ...
Marion Simonetta‐Moreau, Pierre Karam, Anne Forestier, Bertrand Degos   +3 more
wiley   +1 more source

Tracking Genetic Parkinson's Disease with Molecular Imaging: A Systematic Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease (PD) is a worldwide, complex neurodegenerative disorder influenced by both genetic and environmental factors. Around 15–20% of PD cases are linked to genetic mutations, providing insights into the disease's pathogenesis.
Chiara Meneghini, Luca Gallo, Arianna Sala, Enza Maria Valente, Micol Avenali, Silvia Paola Caminiti   +5 more
wiley   +1 more source

Apathy in Parkinson's Disease: Distinguishing Overlapping Symptoms Via Network Analysis

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Anxiety, fatigue, and excessive daytime sleepiness (EDS) frequently co‐occur in Parkinson's disease (PD) and can influence the clinical determination of apathy. Objective To distinguish patient‐reported apathy from other non‐motor symptoms.
Joseph Seemiller, Abhimanyu Mahajan, Christopher B. Morrow, Joseph F. McGuire, Dawn Bowers, Kelly A. Mills, Gregory M. Pontone   +6 more
wiley   +1 more source

TREATMENT WITH A CHOLINERGIC PRECURSOR IN AN ANIMAL MODEL OF CEREBROVASCULAR DISEASE: INSIGHTS INTO MECHANISMS OF NEUROPROTECTIVE ACTIVITY

, 2017
Cholinergic hypofunction is a common trait of adult-onset dementia including Alzheimer’s disease (AD) and vascular dementia (VaD). Cholinergic replacing approaches represent an obvious strategy for treating cognitive dysfunctions due to impaired ...
AMENTA, Francesco, Martinellia, Ilenia, TAYEBATI, Seyed Khosrow, MORUZZI, MICHELE, TOMASSONI, Daniele   +4 more
core   +1 more source